Saakshi Medtech and Panels Limited H1 FY26 Concall Decoded:31% revenue surge, aerospace finally takes off, and management casually drops a ₹500-crore ambition

1. Opening Hook

Remember when SME concalls used to be about survival, not ambition? Saakshi Medtech just walked into H1 FY26 and said, “We’re done restructuring—now watch us scale.” A shiny new 41,000 sq. ft. facility, EBITDA flirting with 19%, and aerospace customers suddenly behaving like repeat buyers, not audit tourists.

Management sounded confident without sounding reckless—rare in SME land. Rental costs are being killed, margins are behaving, and even long-pending stories like aerospace and radiators are finally moving from “pipeline” to “production.”

But don’t get carried away yet. Order visibility is still quarterly, depreciation hasn’t fully hit, and guidance is… philosophical. Read on—because beneath the optimism lies a very execution-heavy second half.

2. At a Glance

• Revenue up 31% YoY – Growth with receipts, not just PPT slides.
• EBITDA at 18.7% – Cost discipline finally clocked in on time.
• PAT ₹6.6 cr – Profits kept pace, didn’t lag behind growth.
• Capex ~₹15 cr – Expansion funded, stress levels low.
• Debt-to-equity 0.17x – Banker-friendly balance sheet.

3. Management’s Key Commentary

“H1 FY26 marks the start of scaling up.”
(Translation: restructuring era is officially over 😏)

“The new integrated facility will eliminate over ₹2 crore in annual rentals.”
(Goodbye landlords, hello operating leverage.)

“Aerospace revenue grew seven-fold YoY.”
(Certifications finally started paying rent.)

“Integrated Control Systems grew 40% YoY.”
(OEMs stayed loyal, volumes showed up.)

“We are in discussions with two Tier-1 aerospace customers.”
(Audits passed; real money pending.)

“Radiator business will kick in post Phase-2 completion.”
(New vertical loading… slowly.)

“We don’t see major capex beyond ₹5 crore now.”
(Capex cycle nearing its end, finally.)

4. Numbers Decoded